Seth Bilazarian, MD, discusses the limitations of Schrage, Ibrahim, et al. published in Circulation comparing patients in cardiogenic shock treated with balloon pump and the Impella® heart pump.
The NCSI Study is based on adopting the best practices algorithm focused on identifying shock early and unloading using Impella devices before PCI, reducing use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.
The STEMI DTU pilot trial demonstrated for the first time that LV unloading using the Impella CP® heart pump with a 30-minute delay before reperfusion is safe and feasible
The clinical, preclinical, and basic research of A-CURE focuses primarily on the use of the Impella® heart pump, a transvalvular microaxial flow pump, as the means to unload the heart.
This study shows that presence of CTO in patients with coronary artery disease (CAD) with ischemic heart failure results in adverse long-term prognosis.
